IGF-1 LR3 0.1mg Research Peptide
IGF-1 LR3 (Insulin-like Growth Factor-1 Long R3) is a synthetic, recombinant analogue of insulin-like growth factor 1 (IGF-1) engineered with an arginine substitution at position 3 and a 13-amino acid N-terminal extension. These modifications significantly reduce its binding affinity for IGF-binding proteins (IGFBPs), extending its half-life from approximately 10 minutes (native IGF-1) to approximately 20–30 hours. This makes IGF-1 LR3 a highly useful research tool for studying IGF-1 receptor signaling over extended time windows without continuous administration. This 0.1mg vial provides research-grade IGF-1 LR3 at ≥99% purity, HPLC and MS/MS verified.
Research Background
IGF-1 LR3 was developed as a research tool to overcome the limitations of native IGF-1’s rapid IGFBP sequestration in biological systems. It binds to the IGF-1 receptor (IGF-1R) with high affinity, activating downstream PI3K/AKT/mTOR and RAS/MAPK/ERK signaling cascades. Research applications include skeletal muscle hypertrophy and atrophy models, satellite cell proliferation studies, neuroprotection research, metabolic studies examining insulin receptor cross-reactivity, and cancer biology models studying IGF-1R pathway dysregulation.
Compound Specifications
- Format: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Quantity: 0.1mg per vial
- Storage: −20°C, protected from light
- Molecular Weight: ~9,117 Da
- Half-life: ~20–30 hours (vs ~10 min native IGF-1)
Certificate of Analysis
All IGF-1 LR3 vials are third-party tested by independent ISO-certified laboratories. HPLC and MS/MS validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
